Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Link Pharma Chem's annualized net income for the quarter that ended in Mar. 2026 was ₹-16.3 Mil. Link Pharma Chem's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹127.9 Mil. Therefore, Link Pharma Chem's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -12.78%.
The historical rank and industry rank for Link Pharma Chem's Return-on-Tangible-Equity or its related term are showing as below:
BOM:524748'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -9.48 Med: 5.48 Max: 13.92
Current: 0.6
During the past 13 years, Link Pharma Chem's highest Return-on-Tangible-Equity was 13.92%. The lowest was -9.48%. And the median was 5.48%.
BOM:524748's Return-on-Tangible-Equity is ranked worse than 72.1% of 1570
companies
in the Chemicals industry
Industry Median: 5.88
vs BOM:524748: 0.60
Link Pharma Chem (BOM:524748) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Link Pharma Chem Return-on-Tangible-Equity Related Terms
Link Pharma Chem Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Link Pharma Chem's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524748 vs DOW: Return-on-Tangible-Equity Comparison
For the Chemicals subindustry, Link Pharma Chem's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Link Pharma Chem Return-on-Tangible-Equity vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Link Pharma Chem's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Link Pharma Chem's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -12.78% mean?
Link Pharma Chem (BOM:524748) has a Return-on-Tangible-Equity of -12.78% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Link Pharma Chem and its competitors. According to the industry distribution chart, Link Pharma Chem ranks #1132 out of 1570 companies in the Chemicals industry, placing it in the top 72.1%.
Is Link Pharma Chem's Return-on-Tangible-Equity too high?
Link Pharma Chem's current Return-on-Tangible-Equity is -12.78%. Based on the distribution chart, Link Pharma Chem ranks #1132 out of 1570 companies in the Chemicals industry, which is below the industry midpoint. Overall, Link Pharma Chem has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Link Pharma Chem's Return-on-Tangible-Equity compare to DOW?
According to the Chemicals industry distribution chart, Link Pharma Chem ranks #1132 out of 1570 companies for Return-on-Tangible-Equity. This places Link Pharma Chem in the lower half of its industry. The industry median Return-on-Tangible-Equity is 5.88. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Chemicals company?
The median Return-on-Tangible-Equity among Chemicals companies is 5.88, based on 1,570 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Link Pharma Chem and its competitors. For the Chemicals industry, the median Return-on-Tangible-Equity is 5.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Link Pharma Chem's current Return-on-Tangible-Equity is -12.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Link Pharma Chem stock overvalued right now?
Based on GuruFocus' analysis, Link Pharma Chem (BOM:524748) is currently considered Possible Value Trap. The stock's GF Value™ is ₹36.15, compared to a current price of ₹25.00 — trading 30.8% below its estimated fair value. The current Return-on-Tangible-Equity is -12.78%. Link Pharma Chem's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Link Pharma Chem (BOM:524748), the current Return-on-Tangible-Equity is -12.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Link Pharma Chem (BOM:524748) Overvalued in 2026?
Based on GuruFocus' analysis, Link Pharma Chem stock appears to be undervalued.
The current stock price of ₹25.00 is trading 30.8% below its estimated GF Value™ of ₹36.15.
GuruFocus considers Link Pharma Chem to be Possible Value Trap.
Key valuation signals for BOM:524748:
Return-on-Tangible-Equity: -12.78%
GF Value™: ₹36.15 vs. price of ₹25.00 (30.8% below fair value)
No single metric tells the full story. See the BOM:524748 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Link Pharma Chem Ltd is engaged in the manufacturing and selling of organic intermediates which are used in pharmaceuticals, agro and speciality chemical industries. The company has its manufacturing location at Nandesari in Gujarat. It operates through single segment which is Chemical manufacturing and generates revenue from the same. The company generates the majority of its revenue from domestic sales.
62GF Score
Get the complete analysis for BOM:524748
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524748 has been successfully added to your 
